KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Intuitive Surgical (ISRG) Research & Development (2016 - 2025)

Historic Research & Development for Intuitive Surgical (ISRG) over the last 17 years, with Q4 2025 value amounting to $352.9 million.

  • Intuitive Surgical's Research & Development rose 1974.89% to $352.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year increase of 1453.77%. This contributed to the annual value of $1.3 billion for FY2025, which is 1453.77% up from last year.
  • Intuitive Surgical's Research & Development amounted to $352.9 million in Q4 2025, which was up 1974.89% from $329.4 million recorded in Q3 2025.
  • In the past 5 years, Intuitive Surgical's Research & Development ranged from a high of $352.9 million in Q4 2025 and a low of $159.8 million during Q1 2021
  • Its 5-year average for Research & Development is $250.3 million, with a median of $247.2 million in 2023.
  • In the last 5 years, Intuitive Surgical's Research & Development surged by 3309.71% in 2022 and then surged by 655.47% in 2023.
  • Intuitive Surgical's Research & Development (Quarter) stood at $183.4 million in 2021, then skyrocketed by 33.1% to $244.1 million in 2022, then grew by 6.55% to $260.1 million in 2023, then increased by 13.3% to $294.7 million in 2024, then increased by 19.75% to $352.9 million in 2025.
  • Its Research & Development stands at $352.9 million for Q4 2025, versus $329.4 million for Q3 2025 and $313.3 million for Q2 2025.